SCHEMBL25035220

SCHEMBL25035220

CC(C)(C)OC(=O)N1CC2(CCN(c3ccc(-c4ccc(OCc5ccccc5)nc4OCc4ccccc4)cc3F)CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.42
SCD5 Q86SK9 1/20 0.41
PARP1 P09874 5/20 0.40
TNKS O95271 2/20 0.40
TNKS2 Q9H2K2 2/20 0.40
ALOX5AP P20292 2/20 0.40
FEN1 P39748 2/20 0.40
PRMT5 O14744 3/20 0.39
CDK9 P50750 2/20 0.39
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
TLR9 Q9NR96 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
RORC P51449 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31018307 1.00 CYP11B2 (0.42) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL30136015 0.95 PARP1 (0.43) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL25940751 0.95 PARP1 (0.43) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL30830739 0.95 PARP1 (0.42) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL25819356 0.92 CYP11B2 (0.42) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL26642195 0.90 TLR9 (0.46) PRMT5CDK9CCNT1CCNA2CDK2
SCHEMBL30888769 0.89 CYP11B2 (0.41) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL30112341 0.89 CYP11B2 (0.41) CYP11B2SCD5PARP1TNKSTNKS2
SCHEMBL26641312 0.88 GPR119 (0.44) CYP11B2SCD5PRMT5GPR119
SCHEMBL30965537 0.88 SCD5 (0.44) CYP11B2SCD5GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 CYP11B2 3804/4885SCD5 3526/4885PARP1 221/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 CYP11B2 2597/4885SCD5 4086/4885PARP1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.